CPRX — Catalyst Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.52bn
- $1.86bn
- $491.73m
- 99
- 74
- 36
- 80
Annual cashflow statement for Catalyst Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 75 | 39.5 | 83.1 | 71.4 | 164 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 7.04 | 6.36 | 13.1 | 94.5 | 16.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.11 | 5.02 | 13.7 | -37.3 | 30.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | 45 | 60.4 | 116 | 144 | 240 |
| Capital Expenditures | -0.011 | -1.02 | -0.029 | -0.231 | -0.556 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -5 | -10 | 9.24 | -293 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -5.01 | -11 | 9.21 | -294 | -0.556 |
| Financing Cash Flow Items | -0.056 | -0.153 | -0.968 | -13.6 | -13.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0.702 | -8.14 | 1.69 | -10.9 | 141 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 40.7 | 41.2 | 127 | -161 | 380 |